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C A N C E R
Tumor cell–organized fibronectin maintenance 
of a dormant breast cancer population
Lauren E. Barney1, Christopher L. Hall1, Alyssa D. Schwartz1, Akia N. Parks2, Christopher Sparages1, 
Sualyneth Galarza1, Manu O. Platt2, Arthur M. Mercurio3, Shelly R. Peyton1*
Tumors can undergo long periods of dormancy, with cancer cells entering a largely quiescent, nonproliferative 
state before reactivation and outgrowth. To understand the role of the extracellular matrix (ECM) in regulating 
tumor dormancy, we created an in vitro cell culture system with carefully controlled ECM substrates to observe 
entrance into and exit from dormancy with live imaging. We saw that cell populations capable of surviving en-
trance into long-term dormancy were heterogeneous, containing quiescent, cell cycle–arrested, and actively pro-
liferating cells. Cell populations capable of entering dormancy formed an organized, fibrillar fibronectin matrix 
via v3 and 51 integrin adhesion, ROCK-generated tension, and TGF2 stimulation, and cancer cell outgrowth 
after dormancy required MMP-2–mediated fibronectin degradation. We propose this approach as a useful, in vitro 
method to study factors important in regulating dormancy, and we used it here to elucidate a role for fibronectin 
deposition and MMP activation.
INTRODUCTION
Even after apparently successful treatment, disseminated tumor cells 
(DTCs) can remain viable for many years, entering into a prolonged 
period of dormancy before eventual activation and outgrowth (1, 2). 
The presence of these disseminated, largely quiescent tumor cells in 
the bone marrow is a predictive marker of increased metastatic risk 
and poor prognosis (1, 2). It has long been hypothesized that DTCs 
must land in hospitable tissues to grow, and many cells that dissem-
inate to secondary organs are incapable, at least initially, of colonizing 
and proliferating into an overt metastasis (3). However, it is debated 
whether the extracellular matrix (ECM) of the secondary tissue site, 
or any tumor cell–associated remodeling of the said ECM, is a pri-
mary determinant of the fate of DTCs.
Strong evidence is emerging to support that certain ECM proteins 
can promote cell dormancy, including thrombospondin-1 on the 
microvascular endothelium in breast cancer (4) and osteopontin within 
the bone marrow in leukemia (5). In related examples, collagen I 
fibrosis is required for outgrowth of a dormant breast cancer popu-
lation (6, 7), and collagen I–mediated signaling through discoidin 
domain receptor tyrosine kinase 1 (DDR1) is required for reactiva-
tion of dormant breast cancer cells (8). Physical properties of the 
ECM have been implicated as well, in that stiff environments pro-
mote cell proliferation, while softer surfaces support quiescence (9). 
Recent work has demonstrated that changes in the expression of ECM 
proteins can facilitate cell survival and outgrowth. For instance, 
fibronectin is produced by the stroma to support survival of metas-
tasizing lung cancer cells (10). Breast cancer cells have also been 
shown to trigger stromal periostin secretion (11) or produce their 
own tenascin C (12) to metastasize to the lung. Although not directly 
related to dormancy, these latter studies point to the importance of 
the generation of provisional matrices in first mediating survival and 
then outgrowth of disseminated cells.
Although entrance into dormancy and reactivation are contin-
uous and dynamic processes, most dormancy studies use static, 
endpoint measurements in vivo. Because of the difficulty of live 
imaging in vivo and the prohibitive cost of high-resolution sam-
pling in time, these studies inherently cannot simultaneously cap-
ture the spatial dynamics and heterogeneity of microenvironment 
components alongside the ability to visualize the proliferation or 
quiescence of an entire cell population. An endpoint measurement 
such as immunohistochemistry can identify colocalized Ki67- 
labeled cells with ECM (4, 13), which only correlates these ECM 
proteins with cell proliferation. A major limitation with these studies 
is that there is no way to determine whether an individual Ki67− 
cell will eventually proliferate. Intravital imaging has started to ad-
dress this problem, but it cannot yet view cells deep in the animal 
(5, 14–16), and it is nearly impossible to search an organ for an in-
dividual or small group of dormant cells. Despite these limitations, 
key recent in vivo studies have linked dormant cell outgrowth to 
fibrosis (6), transmembrane 4 L six family member 1 (TM4SF1) (8), 
miR-138 (17), and most recently, laminin and smoking (14) in the 
lung. These efforts have required large pools of mice, particularly cost 
prohibitive for most laboratories. We sought to find an alternative 
strategy that would enable higher throughput screens across cell 
sources and ECMs to determine how a population of disseminated 
cells enters dormancy and eventually transitions to overt metastatic 
outgrowth.
We developed a cell culture system capable of inducible and 
reversible population-level dormancy, where we can track the dynamics 
of individual cells and cell clusters. Using live imaging, we reveal 
substantial heterogeneity across a dormant population of cells, simul-
taneously consisting of Ki67-positive, Ki67-negative, senescent, and 
actively proliferating cells. Across a diverse set of human breast cancer 
cell lines, those that could enter long periods of dormancy consistently 
produced and assembled a fibronectin matrix through 51 integrin– 
mediated adhesion and rho-associated kinase (ROCK)–mediated 
cell tension. The ability to proliferate after dormancy depended on 
the ability to degrade the fibronectin matrix with matrix metallo-
proteinase 2 (MMP-2). We demonstrated that the recipient ECM 
determined successful entry into and exit from dormancy, providing 
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clues toward previously under-appreciated ECM- associated thera-
peutic targets to prevent reactivation of dormant cell populations.
RESULTS
In vitro model of dormancy reveals a heterogeneous 
population of cell cycle–arrested and proliferative cells
We combined our established system of defined ECM protein surfaces 
(18, 19) with serum deprivation to force cell populations into a dormant- 
like state (Fig. 1A). We define population level, or tumor dormancy 
[here referred to as “dormancy” (20)], as a cell population that is not 
increasing in number but remains viable for an extended time (at least 
4 and up to 12+ weeks). The cell culture medium was serum and 
growth factor free but contained amino acids, vitamins, sugars, and 
salts. Continuous culture under this serum deprivation condition 
decreased both cell number and number of actively cycling cells (Ki67+) 
over the first 10 to 14 days, and we could rescue cell growth (both 
total number and Ki67+) by reintroducing serum (ZR-75-1 cells 
shown as typical example in Fig. 1A). This is indicative of a revers-
ible, quiescent phenotype in some subpopulation of cells within the 
dormant culture.
We performed a screen on 23 human breast cancer cell lines to 
find those capable surviving 8 weeks of serum deprivation (Fig. 1B) and 
our ability to rescue growth after 7 days in serum or growth factor 
cocktails (Fig. 1C). Only eight cell lines had viable cells remaining 
after 8 weeks of serum starvation, and of those, only five cell lines 
could be restimulated to grow. For some of the poor-performing cell 
lines (e.g., ZR-75-1), we could boost their serum deprivation survival 
by increasing the cell density (fig. S1). We then asked whether the 
ECM proteins presented on the cell culture surface affected this re-
versible dormancy by performing the assay on tissue culture plastic, 
on a pure collagen 1 surface, or on a mixture of proteins reflective of 
Fig. 1. Serum withdrawal induces a reversible dormant phenotype in breast cancer cells. (A) ZR-75-1 breast cancer cell line number and proliferation (Ki67 staining) 
over time with serum withdrawal (red) and recovery in full serum (blue). (B) Survival of breast cell lines on TCPS (TC), collagen I coverslips (Col), or a mixture of ECM pro-
teins inspired by those found in the bone marrow (BM)–functionalized coverslips. Average time to decrease confluence from 100 to 25% (scored by visual inspection by 
the same observer) is displayed on the left in red, and conditions where viable cells were detected at 8 weeks in culture are labeled on the right in black. (C) Best-performing 
cell lines were cultured on TCPS for 6 weeks and stimulated with varying media conditions (GF, growth factor cocktail; CM, conditioned medium from mesenchymal stem 
cells). SF, serum-free. Heat map shows increase in confluence over 7-day stimulation in blue. (D) Ki67 quantification of BT549 and ZR-75-1 plated on TCPS and (E) of 
HCC 1954 on TCPS or collagen. Black, 10% serum control; blue, day 28 serum-free culture; green, 7-day recovery. (F) Immunofluorescent staining for phospho-p38 (red; 
Thr180/Tyr182) and 4′,6-diamidino-2-phenylindole (DAPI) (blue) in HCC 1954 on collagen coverslips after 2 and 28 days of serum starvation (scale bar, 100 m). (G) Popula-
tion quantification of HCC 1954 via costaining of Ki67, p21, and senescence-associated -galactosidase (-gal). (H) BrdU- and EdU-labeling experiment schematic and 
results for HCC 1954 on collagen. Black, double negative; red, BrdU positive; green, EdU positive; blue, double BrdU and EdU positive. P < 0.05 was considered statistically 
significant. P < 0.05 is denoted with *P < 0.05, and ****P ≤ 0.0001.
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those found in the bone marrow (a common site for clinical dormancy; 
Fig. 1B). These environments were made via covalently cross-linking 
proteins to a glass coverslip, with our previously published method 
(18). Largely, the ability of the serum deprivation stress to reduce cell 
culture confluency was independent of the ECM substrate, with few 
exceptions (most notably, MDA-MB-468, BT549, and MDA-MB-231). 
However, our ability to detect viable cells with a live-dead assay after 
a full 8 weeks of serum deprivation was highly substrate dependent 
for those cultures that did survive (Fig. 1B, right), with only the 
HCC 1954 and Hs578T cell lines having viable cells left on all ECMs.
From Fig. 1B, we chose to further investigate the HCC 1954, BT549, 
and ZR-75-1 cell lines, as these cell lines represent different clinical 
subtypes (HER2+, triple negative, and luminal, respectively), and they 
exhibited high, moderate, and low survival under serum starvation, 
respectively. Serum-free culture over 4 weeks induced population- 
level dormancy in these cell lines, defined by few Ki67+ cells (Fig. 1, 
D and E). When stimulated with serum, each cell population recov-
ered their proliferation within a week. The HCC 1954 cell line only 
fully recovered the Ki67+ cell population on a collagen I–coated 
coverslip not on tissue culture polystyrene plates (TCPS) (Fig. 1E). 
To more deeply examine whether ECM was important in promot-
ing survival in this assay, we screened serum-free survival of all 
three cell lines across several ECM proteins and protein combina-
tions, varying amounts of those proteins, and different substrate 
stiffnesses. Of all these variables, we found that ECM protein iden-
tity, specifically collagen I, most notably promoted cell survival during 
serum starvation (fig. S2). For this reason, all subsequent exper-
iments were performed using HCC 1954 on this substrate unless 
otherwise noted.
After 4 weeks of serum withdrawal, 10 to 20% of cells were still 
Ki67+, so we asked whether cells were actively proliferating, cell cycle 
arrested, or more homogeneously quiescent (Fig. 1, D and E). First, 
we observed that a subset of cells expressed active p38 after 28 days 
of serum deprivation (Fig. 1F), characteristic of a well-characterized 
dormancy program in vivo (21). Second, time-lapse imaging identified 
a small population of proliferating cells undergoing mitosis (movie S1). 
Third, we found that expression of p21 was significantly elevated in 
our dormant population, indicative of cell cycle arrest (fig. S3C). 
When we costained the population of cells after 2 and 28 days of serum 
deprivation for Ki67, p21, and senescence-associated -galactosidase, 
we found that most cells were Ki67+ after 2 days, but there was a 
richly diverse set of cell cycle states across the population after 28 days 
(Fig. 1G). Most of the population was simultaneously p21+ and 
Ki67−, indicating that a large fraction of the surviving population was 
both cell cycle arrested and nonproliferative. However, cells remained 
that were negative for all markers, or were Ki67+, and we speculated 
that some of these cells were responsible for maintaining cell numbers 
after long periods of serum deprivation and possibly responsible for 
regrowth when serum was replenished in the “recovery” experiments.
To directly test whether individual cells could regain proliferation 
after dormancy, we sequentially labeled cells with 5-bromo-2′- 
deoxyuridine (BrdU) at day 25 of serum starvation, and 5-ethynyl- 
2′-deoxyuridine (EdU) immediately upon serum-stimulated recovery, 
and followed them for either three or seven additional days. We saw a 
large population of cells that did not incorporate BrdU during serum 
deprivation but did incorporate EdU during reactivation; that is, 
cells were quiescent during starvation but regained proliferation 
(Fig. 1H). When repeating this labeling experiment during sequen-
tial 72-hour periods of dormancy (i.e., label with BrdU during serum 
starvation and then label with EdU during a second period of serum 
starvation), we identified small populations (~7%) that were positive 
for either BrdU or EdU but not both (Fig. 1H, serum 3 days). Last, the 
very small percentage of double-positive cells decreased from days 3 
to 7, reflective of the cells slowly cycling during serum deprivation, 
and continued proliferation after serum reintroduction.
This method of serum deprivation–mediated dormancy allowed 
us to create a population of quiescent (Ki67−) cells, stable for 4 to 
8 weeks (fig. S3A). We wondered whether these cells were a result of 
selection for cells that were robustly “dormancy capable.” When we 
performed successive rounds of serum removal and recovery on a 
single culture, we observed no change in the number of surviving or 
regrowing cells compared to a naïve population (fig. S3B), suggesting 
that we recapitulated the heterogeneity of the original parental pop-
ulation upon regrowth.
Fibronectin secretion and organization is required 
for extended dormancy
We observed that many of the surviving cells had a spread, adherent 
phenotype, with some larger clusters of cells assembled into semi- 
adhered spheroids (movie S1). This suggested to us that surviving 
dormant retained both strong cell-matrix and cell-cell adhesions. Since 
our initial screen identified ECM protein identity as a key factor 
in serum-free cell survival, we hypothesized that the dormant cell 
cultures may secrete ECM proteins to support survival. We performed 
liquid chromatography–mass spectrometry (LC-MS) on HCC 1954 
samples enriched for ECM proteins at days 2 and 28 of serum depri-
vation and again after 1 week of recovery in full serum (fig. S4, A 
and B). We were excited to find many collagens, glycoproteins, and 
proteoglycans that were not detectable at day 2, appeared at day 28, 
and subsequently disappeared when cell cultures were serum recovered 
(fig. S4, A and B), including fibronectin (isoform 6).
We were particularly interested in ECM proteins with known, strong 
roles in integrin-mediated adhesion, such as fibronectin, laminins, 
collagens, vitronectin, and osteopontin. Many of these were detected 
at day 28 of serum-free culture by LC-MS, and some of them were 
no longer detectable after recovery in serum (fig. S4B). When we 
looked more closely at these proteins via immunofluorescence, we saw 
that laminins (identified with a pan-laminin antibody), vitronectin, 
and osteopontin were all detected at increased levels during the 
dormant HCC 1954 culture, but all appeared intracellular by visual 
inspection (Fig. 2A). Serum-starved cells can uptake ECM to pro-
mote survival (22), potentially explaining the intracellular distribution 
of these proteins we observed. Fibronectin was deposited at high 
amounts at the day 28 time point (Fig. 2A), and we observed this 
fibronectin secretion phenotype consistently across all three cell lines 
we tested (fig. S5A). In particular, the HCC 1954 cells organized a 
dense fibronectin matrix over 28 days of dormancy, on both TCPS 
and collagen surfaces (fig. S5B). They did not assemble fibronectin 
during 28 days of culture in serum-containing medium on any ECM, 
demonstrating that this secretion happens as a result of serum star-
vation, not normal growth culture.
When the cells were cultured in serum-free conditions and then 
these same cells were recovered in situ with complete serum for 
7 days, the fibronectin matrix was locally degraded where we saw 
high densities of cells (Fig. 2A and fig. S6A). We hypothesized that 
cells were activating MMPs to degrade the fibronectin. Total MMP 
activity was measured with a fluorometric assay, and MMP activity 
was high in cells under normal growth conditions but undetectable 
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in the dormant cell cultures (Fig. 2B). MMP activity was recovered 
with 1 week of recovery culture in serum, suggesting that MMPs 
were involved in the fibronectin degradation during reactivation. 
Specifically, zymography revealed that cathepsins S and V and MMPs 
2 and 9 were low, but detectable, in normal growth conditions. 
These decrease during the serum-free culture (with the exception of 
MMP-2), and cathepsin V and MMPs 2 and 9 were highly activated 
during growth recovery (fig. S6, B and C). Last, when the cells were 
cultured with a pan-MMP inhibitor (GM6001; 25 M) during serum- 
stimulated recovery, HCC 1954 regrowth was reduced during serum 
recovery (Fig. 2C), suggesting that MMP activation and fibronectin 
degradation are beneficial for regrowth after dormancy. Inhibition of 
cathepsin activity with E64 (5 M) did not inhibit reactivation and 
outgrowth, suggesting that outgrowth is MMP, but not cathepsin, 
dependent (fig S6D).
To test whether the presence of a fibronectin-rich ECM directly 
supports long-term cell survival during serum deprivation, we allowed 
the dormant HCC 1954 cultures to assemble the insoluble fibronec-
tin matrices over the 28 days of serum deprivation, and then, we 
decellularized these samples and reseeded new, naïve cell cultures 
onto them. When these cells were subjected to the long-term serum 
deprivation on these decellularized, fibronectin-rich matrices, we 
found that HCC 1954 and multiple other cell lines had visibly im-
proved survival compared to the collagen surfaces across several 
cell lines (Fig. 2D and fig. S5C). This suggests that fibronectin 
promotes dormant cell survival during the serum starvation. How-
ever, some cell lines (AU565 and HCC 1419) showed no ability to 
survive serum deprivation in the original screen and also did not 
show improved survival with a decellularized ECM (fig. S4C); thus, 
fibronectin is not sufficient to support entrance into dormancy by 
itself. We also surmised that the structure of fibronectin is important 
in this assay because when we covalently coupled monomeric fibronec-
tin to a coverslip, cells did not survive well (Fig. 2D). Monomeric 
fibronectin did not support survival as well as collagen (Fig. 2D and 
fig. S5D).
Dormant cells assemble fibronectin via  
cancer cell–secreted TGF
Because matrix assembly is classically stimulated by transforming 
growth factor– (TGF) signaling, we explored whether TGF 
signaling affected the survival of dormant cells. When we provided 
cell cultures with exogenous TGF1 (1 ng/ml) or TGF2 (2 ng/ml) 
at every regular medium change, we saw no effect on cell survival at 
day 7 (Fig. 3A). Similarly, inhibition of TGF receptor signaling with 
LY-364947, a selective and adenosine 5′-triphosphate–competitive 
inhibitor of TGFRI, did not affect day 7 survival (Fig. 3A). When 
the dormant cell cultures were exposed to the inhibitor over 28 days, 
however, cell survival was significantly decreased, and we observed a 
marked decrease in the fibronectin matrix (Fig. 3, B and C). Continuous 
treatment of the cultures with exogenous TGF1 or TGF2 for the 
Fig. 2. Dormant cells up-regulate extracellular fibronectin specifically during serum withdrawal. (A) Top, immunofluorescence for matrix proteins and DAPI in HCC 
1954 on collagen in serum-free medium for 2 and 28 days. Bottom, immunofluorescence and for fibronectin in HCC 1954s grown for 28 days or serum-starved for 28 days 
and recovered in situ for 1 week (blue, DAPI; green, fibronectin; pink, laminin; red, collagen I, vitronectin, or osteopontin, as labeled). Scale bar, 100 m. (B) Total MMP 
activity of HCC 1954 cells on collagen coverslips (C) Number of nuclei resulting from reactivation of dormant cells treated with a pan MMP inhibitor for 7 days (MMPi; 
GM6001, 25 M) or control (serum-containing media, no inhibitor). (D) HCC 1954 day 7 survival on collagen, fibronectin (FN), or HCC 1954 day 28 decellularized ECM 
(decell ECM) coverslips.
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entire 28-day serum deprivation culture either increased or main-
tained survival, respectively (Fig. 3, B and C). Analysis of the culture 
supernatant demonstrated that HCC 1954 express undetectable levels 
of TGF1 and TGF3 (Fig. 3D) but high levels of TGF2 at day 28 
of serum-free culture, suggesting that serum starvation stimulates 
TGF2 secretion, which initiates fibronectin matrix remodeling and 
the survival of dormant cultures.
Fibronectin is assembled via 51 integrin–mediated tension 
and mediates survival via adhesion through v3 and  
51 integrins
Fibronectin assembly occurs via adhesion through 51 integrin 
and downstream RhoA activation, which then activates rho kinase 
(ROCK), generating tension to expose cryptic self-assembly sites in 
fibronectin, inducing polymerization (23–26). The v3 and 51 integrin 
heterodimers bind to fibronectin with high affinity, and we observed 
that these subunits were transcriptionally up-regulated in our 
fibronectin-producing dormant cells (fig. S7). We tested whether 
this pathway of fibronectin assembly was important for dormancy 
phenotype by inhibiting ROCK (Y-27632). We administered Y-27632 
to cell cultures during serum deprivation during the first 7 days (en-
trance into dormancy), or continuously over all 28 days (long-term 
dormant survival), or lastly, we allowed the dormant cells to build 
up a fibronectin matrix for the first 21 days of dormancy and added 
the inhibitors during days 21 to 28 (Fig. 4A).
The maximum dose of Y-27632 (10 M) inhibited survival of 
cells over the first 7 days of serum-free culture on collagen-coated 
coverslips (Fig. 4B, dark blue bars). This maximum dose also inhibited 
cell survival when we administered the inhibitor after cells were 
allowed to preestablish the fibronectin matrix (Fig. 4, B and C) and 
when we seeded cells onto a decellularized ECM (Fig. 4D). However, 
10- and 100-fold lower doses of Y-27632 did not affect survival 
during the first 7 days but prevented survival of cells when ad-
ministered over the full 28 days of serum deprivation (Fig. 4E). When 
we supplemented the culture with soluble fibronectin (10 g/ml) to 
potentially jump-start the matrix, this promoted survival over the 
28 days of serum-free culture, even in the presence of Y-27632 
(Fig. 4, G and H). This suggests that cells use ROCK to secrete and 
assemble fibronectin to survive serum deprivation culture. Maximum 
doses of ROCK inhibitor prevented cell survival in all cases, but 
these lower doses allowed us to observe the more specific role of 
ROCK in fibronectin assembly and long-term survival.
Inhibiting 5 integrin did not affect survival on collagen over the 
first 7 days (Fig. 4B, green bar), but it reduced cell survival when 
dosed after establishment of the fibronectin matrix (from days 21 to 28, 
Fig. 4C). When we seeded cells onto a decellularized matrix while 
inhibiting 5 integrin, we saw no change in survival over the first 
7 days (Fig. 4D). Last, inhibiting 5 integrin function during the 
entire 28-day duration of the experiment inhibited cell survival under 
serum deprivation (Fig. 4E). We also saw an absence of fibronectin 
staining at day 28 in all these inhibitor conditions (Fig. 4F). Collec-
tively, these results suggest that cells require 5 integrin to create the 
organized fibronectin matrices during serum deprivation.
When 1 integrin, which dimerizes with many alpha subunits 
(including 5), was similarly blocked, there was minimal ability for cells 
to survive during serum starvation, regardless of when we applied 
the treatment [including seeding cells onto decellularized matrices 
(Fig. 5, B to D)]. This demonstrates that 1 integrin was driving 
adhesion to both the collagen and fibronectin matrices. To more 
specifically target adhesion to fibronectin, we used cilengitide, a cyclic 
RGD drug that reduces fibronectin binding primarily via v3 and 
v5 integrins (27). Cilengitide treatment did not affect the number 
of cells adhered to the collagen coverslip (Fig. 5B), but it was highly 
effective at disrupting survival when the dormant cells had assembled 
Fig. 3. TGF2 stimulates fibronectin matrix production that mediates survival during mitogen withdrawal. (A and B) Survival of HCC1954 under control, TGF 
receptor inhibition (LY-364947, 5 M), and TGF1 (1 ng/ml) or TGF2 (2 ng/ml) stimulation over (A) 7 days or (B) 28 days. (C) Immunofluorescence for fibronectin (green) 
and DAPI (blue) at day 28. (D) Expression of secreted TGF1, TGF2, or TGF3 in serum-starved cultures at 2 and 28 days in culture. P < 0.05 is denoted with *, P ≤ 0.01 with 
** and P ≤ 0.0001 with ****.
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a fibronectin matrix (Fig. 5C) and when cells were seeded onto 
decellularized matrices containing dense fibronectin (Fig. 5D). 
Although there is some evidence that v3 integrin can bind to 
denatured collagen (28), in our cells, cilengitide appeared to reduce 
adhesion to fibronectin but not to collagen-coupled coverslips.
We performed a small screen of tyrosine kinases to identify pathways 
activated during adhesion to the decellularized fibronectin matrices. 
Across this screen, only extracellular signal–regulated kinase (ERK) 
was highly phosphorylated in both the dormant cell cultures and 
during adhesion to the decellularized ECMs (fig. S8, A to E). Phar-
macological inhibitors to focal adhesion kinase (FAK), mitogen- 
activated protein kinase (MAPK) kinase (MEK), and ERK all decreased 
cell survival over the first 7 days of serum starvation on both the 
collagen- and fibronectin-coupled coverslips and decellularized ECMs 
Fig. 4. Dormancy-associated fibronectin is assembled via 51 integrin and ROCK to mediate survival. (A) Experimental timeline of inhibitor dosing. Day 7 experiments 
were dosed continually through a day 7 endpoint; day 28 experiments were dosed continually through a day 28 endpoint; separate cultures were established for 21 days, 
where inhibitor dosing was initiated for an additional 7 days (“dose-established culture”). (B) Day 7 survival of HCC 1954 on collagen with inhibitors dosed at seeding 
and every medium change. (C) Survival of cells with inhibitors, dosed after establishment of dormant culture for 21 days and then subsequent dosing at every medium 
change through days 21 to 28. (D) Day 7 survival of HCC 1954 on decellularized matrix with inhibitors dosed at every medium change. (E) Day 28 survival of cells with 
inhibitors dosed at seeding and every medium change throughout the entirety of the experiment. Green, 5 integrin function affecting antibody; blue, Y-27632 (ROCK 
inhibitor at various concentrations). (F) Immunofluorescence for fibronectin (green) and DAPI (blue) at day 28 on collagen with inhibitors dosed for the entire 28-day 
time period. Scale bar, 100 m. (G) Immunofluorescence for fibronectin (green) and DAPI (blue) at day 28 on collagen with exogenous fibronectin (10 g/ml) or fibronec-
tin with Y-27632 (1 M). (H) Day 28 survival of cells under control, exogenous fibronectin, or fibronectin with Y-27632. P < 0.05 is denoted with *, P ≤ 0.001 with *** and 
P ≤ 0.0001 with ****.
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(Fig. 5, B to D). This supports a hypothesis that cells are activating a 
survival pathway driven by v3 integrin–mediated adhesion to the 
assembled fibronectin matrix, downstream of ERK pathway activation 
during this serum starvation–induced dormancy in culture.
DISCUSSION
Applied cellular stresses, such as serum deprivation, application of 
drug, or hypoxia, have been used to select for cell populations primed 
for migration and metastasis (29–33). By combining this approach 
with engineered materials, we selected for human breast cancer cells 
that can enter and survive dormancy based on their ability to secrete 
and organize ECM, a phenotype likely missed using traditional cul-
ture platforms or genetic profiling alone (34). Our data support the 
idea that dense fibronectin matrices facilitate long-term survival of 
cancer cells during serum deprivation–induced dormancy. Inhibiting 
51, ROCK, or TGF receptor signaling prohibited fibronectin as-
sembly, eliminating a large population of the surviving dormant cells. 
We suggest a role for 51 in this process, as adhesion to fibronectin 
through 51 integrin is associated with mature focal adhesions 
(23) to support intracellular tension necessary for matrix assembly, 
while adhesion through v3 does so weakly (35). Reactivation and 
outgrowth of the cancer cells after the dormancy period could be 
inhibited by blocking their ability to degrade the fibronectin matrix via 
MMPs. Although they target different aspects of fibronectin matrix 
dynamics, both approaches could be promising mechanisms to elim-
inate dormant cell populations.
Other in vitro models have been used to study spontaneous dor-
mancy (36, 37), using far shorter culture times than our method here. 
Other approaches have used cell lines preselected with distinct 
proliferative or dormant potentials (e.g., the 4T1 and D2 series) 
(7, 17, 38–41). Our study is unique in that a proliferative, heteroge-
neous cell population can be induced to become dormant via serum 
deprivation stress, and the dormancy-competent cells can be subse-
quently reactivated. This approach is analogous to that used in the 
drug resistance studies, where resistant cells are selected via prolonged 
drug-induced stress (42, 43). As one validation of our approach, the 
HCC 1954 cell line capable of showing this dormancy phenotype 
was also identified by Massagué and colleagues as one of two cell 
lines capable of generating dormancy-competent cells in vivo (13).
It has been proposed that dormant micrometastases are a mixture 
of arrested, quiescent, and slow-cycling cells (44). This has not been 
completely clarified since these studies were endpoint analyses, relying 
on defining dormant cells by fixed staining for lack of proliferation 
(Ki67−), DNA synthesis (EdU incorporation), or cell cycle stalling 
(p27+) (4, 21, 38). These studies report that 70 to 80% of Ki67− or p27+ 
are dormant in vivo (4, 21); however, in our culture system, the remain-
ing 20 to 30% of Ki67+ cells could be cell cycle arrested (p21+) or prolif-
erative (Fig. 1G). By imaging live cells during the dormant culture, we 
revealed the presence of persisting cycling, quiescent, and arrested cells, 
a population-wide phenotype reminiscent of tumor dormancy.
We were initially surprised that our data appeared to contradict 
that of Aguirre-Ghiso, who has very thoroughly characterized an 
51 integrin/epidermal growth factor receptor/uPAR/fibronectin 
mechanism, mediating proliferation through ERK not p38 (45, 46). His 
laboratory showed that fibronectin fibrils block the p38 activity char-
acteristic of quiescent cells, which results in sustained ERK signaling 
and proliferation (45, 47, 48). Our data showed that dormant cells 
simultaneously suppressed p38 and activated ERK (fig. S6, A and B). 
However, when looking closer, immunofluorescence revealed that 
high phospho-ERK was ubiquitous (fig. S6E), but phospho-p38 was 
heterogeneous (Fig. 1F). This suggests that this subpopulation of 
dormant cells may be activating the same stress signaling pathway 
described by the Aguirre-Ghiso laboratory (47). In fibroblasts, 
serum withdrawal induces a reversible quiescence, wherein cells 
initially have decreased ERK activity that is eventually regained and 
sustained (49). This report is consistent with the high phospho-ERK 
we report at long dormancy times in cancer cells (fig. S6A). Induction 
Fig. 5. Survival is mediated via adhesion-FAK-ERK signaling. (A) Experimental timeline of inhibitor dosing. Day 7 experiments were dosed continually through a day 7 
endpoint; day 28 experiments were dosed continually through a day 28 endpoint; separate cultures were established for 21 days, where inhibitor dosing was initiated 
for an additional 7 days (dose-established culture). (B) HCC 1954 survival at day 7 on collagen coverslips with selected inhibitors dosed for the duration of the exper-
iment. (C) Survival of HCC 1954 cells after establishment of dormant culture for 21 days and then subsequent dosing with inhibitors through days 21 to 28. (D) HCC 1954 
survival at day 7 with inhibitors when seeded onto HCC 1954 decellularized ECM. Black, control; blue, anti-1 (MAB17781; 1 g/ml); green, FAK inhibitor 14 (10 M); 
purple, PD0325901 (MEK inhibitor, 10 M); red, FR180204 (ERK inhibitor, 20 M); gray, cilengitide (100 M). P < 0.05 is denoted with *, P ≤ 0.001 with *** and P ≤ 
0.0001 with ****.
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of stromal cell senescence is associated with acute activation of p38 
and interleukin-6 release after genotoxic stress in lymphoma (50). 
Therefore, it is possible that the heterogeneous population of p38-high 
and p38-low cells is associated with senescent and quiescent cells, 
respectively, allowing for a population-level dormancy in response 
to serum deprivation stress.
We found that the assembly of fibronectin coincided with en-
trance into a dormant phenotype, and this fibronectin assembly was 
dependent on TGF. Similarly, in cancer-associated fibroblasts, TGF 
is required to create a desmoplastic ECM (51), and oncofetal splice 
variants of fibronectin are stimulated by TGF in glioblastoma (52). 
We observed that cells required ROCK activation to assemble this 
fibronectin matrix, and other work has shown that there may be a 
feedback loop between tension-mediated TGF release and matrix 
assembly (53). Cells responding to TGF are less proliferative but more 
invasive and drug resistant (54). Further, there are other reports of 
a TGF2 regulating the dormancy of tumor cells (21, 55). The well- 
characterized senescence-associated secretory phenotype is associated 
with a secretome that includes TGF (56). This suggests that the 
senescent subpopulation we observed in our cultures (Fig. 1G) may be 
contributing to TGF release and subsequent fibronectin deposition. 
TGF is a promising target in many cancer clinical trials, and we 
suggest here a role for an anti-TGF therapy to prevent survival of 
dormant disseminated cells (57).
Our data suggest that TGF-mediated secretion of fibronectin 
allows cells to maintain a dormant state, agreeing with a recent 
demonstration that the optimal anti-TGF treatment for metastasis 
was during the pre-metastatic stage (58). We also saw that inhibiting 
TGF significantly and substantially reduced the number of surviving 
cells during our dormancy assay (Fig. 3B); however, this could be 
clinically challenging because metastatic cells can disseminate ex-
tremely early during disease progression (59). In our work, fibronec-
tin disassembly occurred during the transition to outgrowth, and 
preventing MMP-mediated degradation of fibronectin may provide 
a better strategy to maintain dormancy and prevent reactivation. 
Together, this suggests that the dynamic control of fibronectin 
secretion/assembly and degradation may be a prerequisite for me-
tastasis via promoting survival and subsequent outgrowth of dormant 
disseminated cells. Fibronectin expression, assembly, and degradation 
have all been featured as critical components of drug resistance and 
metastasis: MAPK and BRAF inhibitors can promote fibronectin 
production to promote drug resistance (60, 61); serum starvation 
induces ECM secretion (62); and hypoxia stimulates matrix remodeling 
and ensuing drug resistance (63). Fibronectin, specifically, prevents 
serum deprivation–induced apoptosis via MEK1 and ERK activa-
tion (64), promotes proliferation (65), and permits survival of growth- 
arrested cells through 51 integrin (66, 67), all in agreement with 
our findings.
We uncovered a mechanism by which dynamic fibronectin 
assembly and disassembly regulate breast cancer cell dormancy, 
which could be targeted to eliminate dormant cells or prevent their 
reactivation. Treatment regimens for eliminating dormant cells are 
difficult due to the stochastic nature of reactivation and the extremely 
long time before relapse (68); however, several treatment regimens 
have been proposed (68–71). One camp argues that since these dor-
mant cells are difficult to find and treat, they could be reactivated 
and sensitized to chemotherapy. This approach obviously comes 
with risk, as a patient would have awakened dormant cells that 
could be drug resistant. Another camp promotes a regimen that would 
keep cells in a dormant state, but this could be costly, lengthy, and 
unnecessary if a patient does not have micrometastases. A more 
exciting possibility is the recent revelation that dormant cells may 
in fact be sensitized to chemotherapy in an ECM-dependent man-
ner (5, 72). This agrees with our suggestion that targeting survival 
signaling from cell-ECM adhesion could be a valuable treatment option. 
There is promising preclinical evidence of efficacy of cilengitide as 
an antimetastatic drug (73–75), and cotargeting dormant cells with 
cilengitide and chemotherapy may prevent metastatic outgrowth by 
eliminating dormant cells at the minimal residual disease stage.
METHODS
Breast cancer cell culture
All cells were cultured at 37°C and with 5% CO2, unless otherwise 
noted. All cell culture supplies were purchased from Thermo Fisher 
Scientific (Waltham, MA). AU565, BT474, HCC 1395, HCC 1419, 
HCC 1428, HCC 1806, HCC 1954, HCC 202, HCC 38, HCC 70, and 
ZR-75-1 were cultured in RPMI supplemented with 10% fetal bovine 
serum (FBS) and 1% penicillin/streptomycin (P/S). BT549, Hs578T, 
MCF7, MDA-MB-231, MDA-MB-468, MDA-MB-231 BoM (bone 
tropic), MDA-MB-231 BrM2a (brain tropic), MDA-MB-231 LM2 
(lung tropic), and SkBr3 were cultured in Dulbecco’s modified 
Eagle’s medium with 10% FBS and 1% P/S. MDA-MB-175 was cul-
tured in Leibovitz’s L-15 medium with 10% FBS and 1% P/S without 
supplemental CO2, and MDA-MB-134 and MDA-MB-361 were 
cultured in Leibovitz’s L-15 medium with 20% FBS and 1% P/S with-
out supplemental CO2. Tropic variants were a gift from J. Massagué 
(76–78); MDA-MB-231 was provided by S. Smith-Schneider; BT549, 
MCF7, and SkBr3 were provided by S. Hughes; and all others were 
provided by M. Niepel.
Biomaterial preparation
Glass coverslips (5, 15, and 18 mm) and poly(ethylene glycol) (PEG)–
phosphorylcholine hydrogels were prepared as previously described 
(18, 19). Briefly, coverslips (Thermo Fisher Scientific) were ultraviolet 
(UV)-ozone treated and silanized through vapor phase deposition 
of 3-aminopropyltriethoxysilane (Sigma-Aldrich) at 90°C for a 
minimum of 18 hours. The coverslips were rinsed sequentially in 
toluene (Thermo Fisher Scientific), 95% ethanol (Pharmco-Aaper, 
Brookfield, CT), and water and dried at 90°C for 1 hour. They were 
then functionalized with 10 g/liter N,N′-disuccinimidyl carbonate 
(Sigma- Aldrich) and 5% (v/v) diisopropylethylamine (Sigma-Aldrich) 
in acetone (Thermo Fisher Scientific) at room temperature for 2 hours. 
Coverslips were rinsed three times in acetone and air-dried. ECM 
proteins (collagen I and natural mouse laminin were purchased from 
Life Technologies; human plasma fibronectin from Millipore; human 
collagen IV from Sigma-Aldrich; recombinant human tenascin C, 
osteopontin, thrombospondin-1, and vitronectin from R&D Systems; 
and laminin 511 and laminin 521 from BioLamina) were covalently 
bound to the glass surface by incubation at room temperature 
for 3 hours and then with methacrylate-PEG-amine [MA(PEG)] 
(10 mg/cm2) (Thermo Fisher Scientific) for 2 hours to block non-
specific protein adsorption, rinsed three times in phosphate-buffered 
saline (PBS), and UV- sterilized before cell seeding. Functionalized 
coverslips were placed into tissue culture plates that were coated with 
polyHEMA (100 g/cm2) to block nonspecific cell adhesion.
For experiments on TCPS, TCPS wells were coated with serum- 
containing medium at 37°C for at least 1 hour before cell seeding to 
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facilitate cell adhesion. ECM proteins were used at 2 g/cm2 unless 
otherwise noted. The Human Protein Atlas (79) was used to determine 
the composition of integrin-binding ECM proteins in human bone 
marrow, which primarily includes collagens, fibronectin, and laminins 
(80). We created a minimalist representation of bone marrow ECM 
that contains proteins known to bind to cancer cells (18), composed 
of 50% collagen I, 15% laminin 521, 12% fibronectin, 8% tenascin C, 
8% osteopontin, 5% laminin 511, and 2% vitronectin by weight. 
Collagen I and natural mouse laminin were purchased from Thermo 
Fisher Scientific (Carlsbad, CA); human plasma fibronectin from 
Millipore (Billerica, MA); human collagen IV from Sigma-Aldrich 
(St. Louis, MO); recombinant human tenascin C, osteopontin, 
thrombospondin-1, and vitronectin from R&D Systems (Minneapolis, 
MN); and laminin 511 and laminin 521 from BioLamina (Matawan, NJ).
Establishment of dormant cell cultures
Breast cancer cells were seeded onto biomaterials in serum-free medium 
using the specified culture medium for each cell line. For 7-day 
experiments on different ECM proteins, protein concentrations, and 
hydrogels in Fig. 1A and fig. S1, cells were seeded at 11,000 cells/cm2. 
For all other experiments, cells were seeded at 47,000 cells/cm2 to 
extend the possible duration. Serum-free medium was changed 
every 2 to 3 days for the duration of the experiment. At specified time 
points, cells were changed to serum-containing medium to grow a 
recovered population. Recovery was assessed after 7 days of growth.
In cases where pharmacological inhibitors were used, inhibitor 
was replenished with every regular medium change. Concentrations 
of inhibitors and antibodies were chosen empirically to not affect 
initial seeding density. Where noted, inhibitors or antibodies were 
included in the serum-free or serum-containing medium at the fol-
lowing concentrations: E64 (Tocris; 5 M), ERK inhibitor FR180204 
(Sigma-Aldrich; 20 M), FAK inhibitor 14 (Sigma-Aldrich; 10 M), 
soluble fibronectin (Millipore; 10 g/ml), anti-5 AF1864 (R&D Sys-
tems; 1 g/ml), cilengitide (Apex Biotechnology; 100 M), anti-1 
MAB17781 (R&D Systems; 1 g/ml), MEK inhibitor PD0325901 
(Sigma-Aldrich; 10 M), pan-MMP inhibitor GM6001 (Millipore; 
25 M), ROCK inhibitor Y-27632, (Millipore; 0.1, 1, and 10 M), 
pan-TGF AB-100-NA (R&D Systems; 20 g/ml), anti-TGFBR1, 
LY-364947 (Sigma-Aldrich; 5 M).
Where noted in specific experiments, medium was supplemented 
with EGF (R&D Systems, Minneapolis, MN; 1 ng/ml), fibroblast 
growth factor 1 (FGF1; R&D Systems; 100 ng/ml), insulin-like growth 
factor 1 (R&D Systems; 100 ng/ml), hepatocyte growth factor (R&D 
Systems; 100 ng/ml), TGF1 (Sigma-Aldrich, St. Louis, MO; 1 ng/ml), 
SDF1 ( stromal cell-derived factor 1 ) (R&D Systems; 100 ng/ml), 
or conditioned medium collected from mesenchymal stem cells to 
stimulate reactivation and growth. Where noted, medium was supple-
mented with a growth factor cocktail for recovery EGF (R&D Systems; 
100 ng/ml), FGF1 (R&D Systems; 100 ng/ml), and TGF1 (R&D 
Systems; 100 ng/ml). In addition, TGF2 (Sigma-Aldrich; 2 ng/ml) or 
TGF1 (Sigma-Aldrich; 1 ng/ml) was supplemented in serum-free 
medium.
Characterization and viability of dormant cell cultures
Viability was assessed after 8 weeks of culture by staining with 4 M 
ethidium homodimer-1 and 2 M calcein AM (Thermo Fisher 
Scientific). Any condition where at least one viable cell was identified 
was considered positive for the presence of viable cells. Proliferation 
was assessed with immunofluorescence for Ki67, G1/S arrest by im-
munofluorescence for p21, and senescence by senescence-associated 
-galactosidase staining (Sigma-Aldrich). Immunofluorescence 
was performed according to standard protocols, and imaging was 
performed using a Zeiss Axio Observer Z1 with color and mono-
chrome cameras or a Zeiss Spinning Disc Cell Observer SD (Zeiss, 
Oberkochen, Germany). The following primary antibodies were used 
for immunofluorescence: BrdU (ab8039, Abcam; 2 g/ml), collagen I 
(ab6308, Abcam; 1:200), EdU (Click-iT EdU, Life Technologies; per 
the manufacturer’s protocol), phosphor Thr202/Tyr204 ERK (no. 4370, 
Cell Signaling; 1:200), fibronectin (no. 563100, BD Biosciences; 
1:200), Ki67 (ab16667, Abcam; 1:200), pan-laminin (ab11575, Abcam; 
1:100), osteopontin (ab8448, Abcam; 1:1000), phosphor Thr180/Tyr182 
p38 (no. 4511, Cell Signaling; 1:800), p21 (ab7093, Abcam; 1:100), 
vitronectin (ab13413, Abcam; 1 g/ml).
BrdU and EdU incorporation and staining
BrdU (10 M; Thermo Fisher Scientific) was dosed for 3 days in 
serum-free medium for 72 hours before the day 28 endpoint. At day 28, 
the BrdU-containing medium was removed; cells were washed once 
in serum-free medium and then stimulated with serum-containing 
or serum-free medium containing 10 M EdU (Thermo Fisher 
Scientific). Cells were fixed after an additional 72 hours or 7 days of 
culture, with regular medium changes. Cells were permeabilized in 
TBS-T (tris-buffered saline plus triton-X 100), and DNA was denatured 
with 1 M HCl (10 min, on ice), 2 M HCL (10 min, room tempera-
ture), and phosphate-citric acid buffer (10 min, room temperature). 
Then, staining for EdU was performed according to the manufacturer’s 
protocol (Life Technologies), and subsequently, BrdU staining was 
performed using antibody labeling (Abcam, ab8039; 2 g/ml).
Decellularized ECMs
Decellularized ECMs were generated from dormant HCC 1954 cell 
cultures (originally seeded on collagen I–functionalized glass coverslips 
at 47,000 cells/cm2 in serum-free culture for 28 days) according to a 
published protocol (81). Briefly, cells were extracted with warm PBS 
containing 0.5% Triton X-100 (Thermo Fisher Scientific) and 20 mM 
NH4OH (Thermo Fisher Scientific), added dropwise, and incubated 
at 37°C for 10 min. Twice the volume, PBS was then added, matrices 
stored at 4°C overnight, and washed carefully with PBS three times. 
Decellularized ECMs were created and stored hydrated at 4°C for 
up to 1 month before use. Decellularized ECMs were transferred to 
new well plates and rinsed once each in PBS and serum-free medium 
before use.
Statistical analysis
Statistical analysis was performed using Prism v6.0b. Data are reported 
as means ± SE. Statistical significance was evaluated using a one-way 
analysis of variance, followed by a Tukey’s posttest for pairwise 
comparisons. For Kaplan-Meier survival analysis, significance was 
determined using a log-rank (Mantel-Cox) test. P < 0.05 is denoted 
with *, P ≤ 0.01 with **, P ≤ 0.001 with ***, P and ≤ 0.0001 with 
****; P ≥ 0.05 is considered not significant (“ns”). 
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/6/11/eaaz4157/DC1
Supplemental Methods
Fig. S1. Heat map of percent decrease in confluence and viability for bottom performing cell 
lines.
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Fig. S2. Survival is maximized on collagen I coverslips.
Fig. S3. Serum-starved cells are cell cycle arrested and nonproliferative.
Fig. S4. Proteomic of ECM produced by HCC 1954 during serum starvation and recovery.
Fig. S5. Dormant cells organize fibronectin.
Fig. S6. Fibronectin is locally degraded during reactivation via MMPs.
Fig. S7. Integrin expression of dormant cells determined by quantitative polymerase chain reaction.
Fig. S8. ERK mediates survival in other cell lines.
Table S1. Inhibitors and activators used in experiments.
Table S2. Antibodies used for immunofluorescence.
Table S3. Integrin and CDKN primers.
Movie S1. Rare cells divide after 4 weeks of serum-free culture.
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